Mp62-03 Aquablation Case Series of 812 Consecutive Men With Luts Due to BPH

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology IV (MP62)1 May 2024MP62-03 AQUABLATION CASE SERIES OF 812 CONSECUTIVE MEN WITH LUTS DUE TO BPH Shawn H. Marhamati, Ishan Kangotra, John Klein, and Inderjit Singh Shawn H. MarhamatiShawn H. Marhamati , Ishan KangotraIshan Kangotra , John KleinJohn Klein , and Inderjit SinghInderjit Singh View All Author Informationhttps://doi.org/10.1097/01.JU.0001008904.63948.3b.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Aquablation was approved by FDA in December 2017. Our single center experience comprising of three Aquablation surgeons collected data on all of our patients in a commercial setting since launching the technology. METHODS: 812 consecutive men with moderate-to-severe BPH symptoms and prostate volumes between 22-263 ml underwent a robotic-assisted Aquablation procedure. Routine procedural characteristics, adverse events, symptom scores, and uroflow were collected. RESULTS: The mean age, IPSS, Qmax, and prostate volume were 69±8, 21±7, 11±6, and 77 ml (range 22-263 ml), respectively. The mean operative time (TRUS in to catheter in), was 56±41 minutes. 14% of patients were in preoperative retention with 94% of those patients passing their trial of voids. 53% of patients in the series were discharged same-day. When subgrouped by prostate artery embolization (PAE) use the non-PAE group were 46% day case versus 56% in the PAE group. Clavien-Dindo Grade III or higher was 3.2%. Prior PAE use had no influence on symptom reduction, uroflow improvement or overall CD Grade III or higher complications. IPSS at 8, 12, 24, and 36 months was 7 or less, Figure 1. Qmax at 3 months was 22 ml/s. Secondary intervention due to recurrent LUTS was 1.6%. CONCLUSIONS: In a commercial, all-comers cohort of patients undergoing Aquablation, safety has been improved and efficacy was consistent against FDA clinical trials. The efficacy outcomes were similar to both WATER and WATER II. Complication rates were similar to WATER (30-80 ml) and better than WATER II (80-150 ml), which was driven by a significant reduction in bleeding risk due to the use of focal bladder neck cautery. Day case Aquablation has also been shown to be a viable option. Download PPT Source of Funding: Potomac Urology Center © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1021 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Shawn H. Marhamati More articles by this author Ishan Kangotra More articles by this author John Klein More articles by this author Inderjit Singh More articles by this author Expand All Advertisement PDF downloadLoading ...